Alcon drops AMD candidate

Article

Following disappointing clinical trial results, Alcon has discontinued its plans to develop anecortave acetate for the prevention of choroidal neovascularization secondary to age-related macular degeneration (AMD).

Following disappointing clinical trial results, Alcon has discontinued its plans to develop anecortave acetate for the prevention of choroidal neovascularization secondary to age-related macular degeneration (AMD).

At the 24-month time point, the compound, which was tested in 2546 patients, had failed to achieve both primary and secondary endpoints, causing Alcon to discontinue four separate studies that were being conducted in the US and Asia.

Although Alcon will no longer study the efficacy of anecortave acetate in the treatment of AMD, the company plans to continue its study of the compound as an anterior juxtascleral depot for the reduction of intraocular pressure in open-angle glaucoma.

Related Videos
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.